Docusign Inc vs Nutrien Ltd — how do they compare? Docusign Inc trades at $71.49 (market cap $13.35B), while Nutrien Ltd trades at $69.9 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 2.5× Docusign Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Nutrien Ltd for 59 Days on average.
| DOCU | NTR | |
|---|---|---|
Market Cap | $13.35B | $33.31B |
Volume | 3,158,858 | 1,330,729 |
Sector | Technology | Basic Materials |
52-Week High | $73.14 | $83.94 |
52-Week Low | $41.75 | $53.64 |
Typical Hold Time | 71 Days | 59 Days |
Enterprise Value | $12.76B | $45.11B |
Dividend Yield | — | 3.15% |
Signals from Pluang's Aura AI — not financial advice
DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).
The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.
Nutrien (NTR) trades at $69.97, down 1.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with revenue stabilizing around $26-28B and net margins improving to 8.44%. Recent news highlights industry headwinds from potential Belarus potash imports, though strong fertilizer prices and cost discipline support cash flow. Analyst consensus remains moderately bullish with a $76.14 price target, representing 9% upside potential from current levels.
Investment outlook balances cyclical fertilizer demand against structural advantages. Near-term risks include competitive pressure from potential Belarus imports and sulfur cost inflation, but North American gas arbitrage and agricultural cycle recovery provide catalysts. With reasonable valuation (P/E 14.16) and 60% analyst buy ratings, the stock offers value for patient investors despite technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →